Format

Send to

Choose Destination
Am J Clin Pathol. 2016 Sep;146(3):294-302. doi: 10.1093/ajcp/aqw111.

MAGI-2 Is a Sensitive and Specific Marker of Prostatic Adenocarcinoma:  A Comparison With AMACR.

Author information

1
From the Department of Pathology, Microbiology, and Immunology.
2
Department of Surgery.
3
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN.
4
From the Department of Pathology, Microbiology, and Immunology Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN. omar.hameed@vanderbilt.edu.

Abstract

OBJECTIVES:

We compared the utility of membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) and α-methylacyl CoA (AMACR) by immunohistochemistry in diagnosing prostatic adenocarcinoma.

METHODS:

Seventy-eight radical prostatectomies were used to construct three tissue microarrays with 512 cores, including benign prostatic tissue, benign prostatic hyperplasia, high-grade prostatic intraepithelial neoplasia (HGPIN), and adenocarcinoma. AMACR and MAGI-2 immunohistochemistry were evaluated by visual and image analysis.

RESULTS:

MAGI-2 and AMACR were significantly higher in adenocarcinoma and HGPIN compared with benign tissue. At H-score cutoffs of 300 and 200, MAGI-2 was more accurate in distinguishing benign from malignant glands than AMACR. Areas under the curve by image and visual analysis were 0.846 and 0.818 for MAGI-2 and 0.937 and 0.924 for AMACR, respectively. The accuracy of MAGI-2 in distinguishing benign from malignant glands on the same core was higher (95% vs 88%).

CONCLUSIONS:

MAGI-2 could represent a useful adjunct for diagnosis of prostatic adenocarcinoma, especially when AMACR is not discriminatory.

KEYWORDS:

AMACR; MAGI-2; Prostate cancer

PMID:
27543977
DOI:
10.1093/ajcp/aqw111
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center